二代测序检测急性髓系白血病可测量残留病
急性髓系白血病(AML)缓解后存在复发风险,需准确评估可测量残留病(MRD),但患者间及患者内遗传多样性使AML缺乏统一MRD标志。二代测序可广泛深度检测残留AML遗传证据,目前尚未被临床接受用于该用途,未来可能 increasingly 用于AML MRD检测。
要点
- AML遗传多样性导致无单一遗传异常可通用作MRD标志。
- 二代测序可广泛深度检测残留AML的潜在遗传证据。
- 二代测序目前尚未被临床接受用于AML MRD检测。
核心结论
- 二代测序未来可能 increasingly 用于AML MRD检测,但目前尚未被临床接受用于该用途。
主要发现
- AML患者间及患者内遗传多样性意味着不同于慢性髓系和急性早幼粒细胞白血病,无单一遗传异常对所有AML MRD病例均具病理特异性。
临床怎么用
- 二代测序可广泛深度检测残留AML的潜在遗传证据,但当前临床不应将其作为AML MRD检测的已接受用途。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukaemia (AML) is a blood cancer characterized by acquired genetic mutations. There is great interest in accurately establishing measurable residual disease (MRD) burden in AML patients in remission after treatment but at risk of relapse. However, inter- and intrapatient genetic diversity means that, unlike in the chronic myeloid and acute promyelocytic leukaemias, no single genetic abnormality is pathognomonic for all cases of AML MRD. Next-generation sequencing offers the opportunity to test broadly and deeply for potential genetic evidence of residual AML, and while not currently accepted for such use clinically, is likely to be increasingly used for AML MRD testing in the future.
引用
- Ghannam J, Dillon LW, Hourigan CS, et al. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. Br J Haematol. 2019. PMID: 31804716. doi:10.1111/bjh.16362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。